FindTrial
Sign In

Effects of branched-chain amino acid on the suppression of recurrence after hepatectomy for patients of liver cirrhosis with hepatocellular carcinoma

Effects of branched-chain amino acid on the suppression of recurrence after hepatectomy for patients of liver cirrhosis with hepatocellular carcinoma - Effects of BCAA on the suppression of recurrence after hepatectomy for patients of liver cirrhosis with hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005200
Enrollment
50
Registered
2011-07-01
Start date
2011-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis with hepatocellular carcinoma

Interventions

take LIVACT orally 3 times per day for 3 years after hepatctomy persons who did not intake LIVACT after hepatectomy performed from January 2004 to December 2007.(control)

Sponsors

Kyoto university hospital, Department of Hepato-Biliary-Pancreatic Surgery and Transplantation
Lead Sponsor
Sapporo medical university hospital, First department of surgery Yamaguchi university hospital, Department of digestive surgery and surgical oncology
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: persons who can intake meal enough hypoalbuminemia (4.0g/dL or lower) Child-Pugh A or B

Exclusion criteria

Exclusion criteria: hepatic encephalopathy serum albumin<2.5g/dL Total bilirubin 3mg/dL or higher

Design outcomes

Primary

MeasureTime frame
disease free interval—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026